Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Nyxoah Appoints New CEO to Drive US Expansion

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at sleepreviewmag.com →

◆ Verified

Fusion42 · 30 September 2026 · Fusion42 review

Nyxoah has appointed Liam Kelly as CEO to lead its US commercial expansion following FDA approval and the launch of its Genio hypoglossal neurostimulation therapy for sleep apnea. The leadership change emphasizes Nyxoah's strategic shift to focus on the US market, reflecting growing momentum in physician adoption.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You need to update your US growth plans as Nyxoah’s US commercial push shows the market for sleep apnea neurostimulators is gaining traction. The new CEO’s deep US medtech experience signals rising competitive stakes and shifting sales dynamics.

◆ Coverage

1 source · 30 Sep 2026

◆ Related on Wire

◆ Topics

Medtechceo-appointmentus-expansionmedtechfda-approvalsleep-apnea